Australian Government Accused of Misusing Funds to Combat E-Cigarettes

Sep.09.2022
Australian Government Accused of Misusing Funds to Combat E-Cigarettes
CAPHRA Coordinator Nancy Loucas criticizes Australian government's anti-vaping campaign as a misuse of public funds.

Nancy Loucas, the executive coordinator of the Asia Pacific Advocates for Tobacco Harm Reduction (CAPHRA), has expressed that the crackdown on e-cigarette retailers in Australia constitutes a serious misuse of public funds, which should be directed towards improving the country's healthcare system.


Before she issued her statement, the government of New South Wales in Australia intensified its warnings to compliant retailers about the risks associated with e-cigarette products. They also continue to back a controversial joint "education campaign" with the Department of Education on the issue of e-cigarettes.


The centerpiece of the event is the "Get the Facts" - Vaping Toolkit aimed at teachers, parents, and adolescent students. CAPHRA stated that despite Deputy Chief Health Officer Dr. Marianne Gale's assurance that the website does not contain "evidence-based resources and educational materials," it should be taken down while its many statements are independently verified.


These claims about electronic cigarettes are either completely exaggerated or, in the worst case scenario, have no scientific basis. The Australian public, regardless of age, needs to have complete confidence in any health statements on government websites. Unfortunately, this campaign is far from factual. Instead, it is filled with blatant lies," said Ms. Lucas.


In a statement that has angered advocates for tobacco harm reduction (THR) throughout the entire Asia-Pacific region, Dr. Gale claimed, "Many people believe that e-cigarettes are either completely harmless or less harmful than traditional cigarettes.


In a recent situation, an Australian chief health officer has been actively informing the public that the harm of vaping is not less than smoking. However, international research strongly refutes this claim. Despite providing no evidence to support her statement, the Australian public continues to receive such costly yet worthless advice. This is a complete embarrassment," she said.


According to CAPHRA, Australians who want to know the truth about vaping should look to New Zealand. Adults can legally use nicotine e-cigarettes there under regulations targeting retailers and manufacturers in 2020. Smokers looking to quit do not need to obtain a prescription from a doctor, unlike in Australia.


Asking doctors to prescribe cigarettes has left 2.3 million smokers in Australia disappointed, not to mention the approximately 20,000 Australians who die each year from smoking-related illnesses. While Australia's overall smoking rate has remained stagnant over the past decade, New Zealand has seen a 50% decrease in its smoking rate, largely due to the availability of legally sanctioned, less harmful alternatives for smokers, according to Ms. Lucas.


CAPHRA has pointed out that the headline of the New Zealand Ministry of Health's "Vaping facts" website states that "vaping is less harmful than smoking".


New Zealand is engaging in a positive dialogue with the public with the goal of achieving a smoke-free nation by 2025, with a smoking rate of 5% or less. In contrast, health leaders in Australia are continuing to ban adults from entering retail stores while using significant public resources to deter the use of e-cigarettes.


Australia's healthcare system is failing miserably. The persistent threats and lies surrounding e-cigarettes will make it almost impossible to achieve the country's goal of reducing smoking rates by 10% in the short term. They need a new strategy to eradicate tobacco, as the current one clearly isn't working," said Nancy Lucas.


CAPHRA, an advocacy group, has amassed almost 15,000 endorsement letters and is urging those who have quit smoking through the use of nicotine-free alternatives to share their stories on www.righttovape.org.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the opinion of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article’s content. The compilation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Cambodia Moves to Draft New Tobacco Control Strategy Targeting Illicit Products and E-Cigarette Spread
Cambodia Moves to Draft New Tobacco Control Strategy Targeting Illicit Products and E-Cigarette Spread
Cambodian Health Minister Cheang Ra has called for the development of a tobacco control strategy for 2027–2031, with the goal of reducing tobacco use by 30% by 2030. The directive was issued during a Tobacco Product Control Committee meeting in Phnom Penh. Priority areas include reducing tobacco use, protecting the public from secondhand smoke, tackling illegal and counterfeit tobacco products, and preventing the spread of e-cigarettes.
Apr.29 by 2FIRSTS.ai
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
VEEV Arrives in South Korea, Completing PMI’s IQOS-ZYN-VEEV Portfolio
VEEV Arrives in South Korea, Completing PMI’s IQOS-ZYN-VEEV Portfolio
Philip Morris Korea has officially launched its VEEV e-vapor brand in South Korea, introducing both the VEEV inPRIME device and VEEBI inPRIME pods. The launch further expands PMI’s smoke-free portfolio in Korea, alongside its IQOS heated tobacco products and ZYN nicotine pouches.
Jun.16
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
According to Bloomberg, Philip Morris International’s Zyn is facing growing competition in the U.S. nicotine pouch market as consumers shift toward moister alternatives such as British American Tobacco’s Velo Plus.
BATPMI
May.22
U.S. Military Nicotine Policy Sparks Debate as Nicotine Pouches Enter Discussion
U.S. Military Nicotine Policy Sparks Debate as Nicotine Pouches Enter Discussion
An opinion article published by Stars and Stripes argued that the Pentagon’s January nicotine clinical guidelines overemphasize abstinence, fail to reflect the reality that about 30% of active-duty personnel use nicotine, and do not address nicotine pouches as potential harm-reduction products.
Industry Insight
Jun.08
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22